Author, as appears in the article.: Ettcheto, Miren; Olloquequi, Jordi; Sanchez-Lopez, Elena; Busquets, Oriol; Cano, Amanda; Regina Manzine, Patricia; Beas-Zarate, Carlos; Castro-Torres, Ruben D.; Luisa Garcia, Maria; Bullo, Monica; Auladell, Carme; Folch, Jaume; Camins, Antoni;
Department: Bioquímica i Biotecnologia
URV's Author/s: Bulló Bonet, Mònica / Folch Lopez, Jaume
Keywords: alzheimer's disease benzodiazepines cognition dementia Alzheimer's disease American academy Amyloid-beta Benzodiazepines Clinical-practice guideline Cognition Cognitive decline Dementia Gabaergic deafferentation hypothesis Impairment Insomnia Long-term use Pharmacological-treatment Risk factors Sleep disturbance
Abstract: Benzodiazepines (BZDs) and Z-drugs are compounds widely prescribed in medical practice due to their anxiolytic, hypnotic, and muscle relaxant properties. Yet, their chronic use is associated with cases of abuse, dependence, and relapse in many patients. Furthermore, elderly people are susceptible to alterations in pharmacodynamics, pharmacokinetics as well as to drug interaction due to polypharmacy. These situations increase the risk for the appearance of cognitive affectations and the development of pathologies like Alzheimer's disease (AD). In the present work, there is a summary of some clinical studies that have evaluated the effect of BZDs and Z-drugs in the adult population with and without AD, focusing on the relationship between their use and the loss of cognitive function. Additionally, there is an assessment of preclinical studies focused on finding molecular proof on the pathways by which these drugs could be involved in AD pathogenesis. Moreover, available data (1990-2019) on BZD and Z-drug use among elderly patients, with and without AD, was compiled in this work. Finally, the relationship between the use of BZD and Z-drugs for the treatment of insomnia and the appearance of AD biomarkers was analyzed. Results pointed to a vicious circle that would worsen the condition of patients over time. Likewise, it put into relevance the need for close monitoring of those patients using BZDs that also suffer from AD. Consequently, future studies should focus on optimizing strategies for insomnia treatment in the elderly by using other substances like melatonin agonists, which is described to have a much more significant safety profile.
Thematic Areas: Aging Biodiversidade Biotecnología Ciências biológicas i Ciências biológicas ii Ciências biológicas iii Cognitive neuroscience Educação física Engenharias iv Geriatrics & gerontology Interdisciplinar Medicina i Medicina ii Medicina veterinaria Neurosciences Nutrição Psicología Química Saúde coletiva
licence for use: https://creativecommons.org/licenses/by/3.0/es/
Author's mail: monica.bullo@urv.cat jaume.folch@urv.cat
ISSN: 16634365
Author identifier: 0000-0002-0218-7046 0000-0002-5051-8858
Record's date: 2023-02-18
Papper version: info:eu-repo/semantics/publishedVersion
Link to the original source: https://www.frontiersin.org/journals/aging-neuroscience/articles/10.3389/fnagi.2019.00344/full
Papper original source: Frontiers In Aging Neuroscience. 11 (344): 344-
APA: Ettcheto, Miren; Olloquequi, Jordi; Sanchez-Lopez, Elena; Busquets, Oriol; Cano, Amanda; Regina Manzine, Patricia; Beas-Zarate, Carlos; Castro-Torres, (2020). Benzodiazepines and Related Drugs as a Risk Factor in Alzheimer's Disease Dementia. Frontiers In Aging Neuroscience, 11(344), 344-. DOI: 10.3389/fnagi.2019.00344
Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
Article's DOI: 10.3389/fnagi.2019.00344
Entity: Universitat Rovira i Virgili
Journal publication year: 2020
Publication Type: Journal Publications
Repositori URV